Sociedad Americana de Hirudoterapia

Optimising hand surgery during COVID-19 pandemic

Retrospective observational study published in J Hand Surg Asian Pac Vol (2021)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Observational studyEnsayos clínicosSaha S et al. · The journal of hand surgery Asian-Pacific volume, 2021

Abstract

Background: With the emergence of the COVID-19 pandemic, most health-care personnel and resources are redirected to prioritize care for seriously-ill COVID patients. This situation may poorly impact our capacity to care for critically injured patients. We need to devise a strategy to provide rational and essential care to hand trauma victims whilst the access to theatres and anaesthetic support is limited. Our center is a level 1 trauma center, where the pandemic preparedness required reorganization of the trauma services. We aim to summarise the clinical profile and management of these patients and highlight, how we modified our practice to optimize their care. Methods: This is a single-centre retrospective observational study of all patients with hand injuries visiting the Department of Plastic Surgery from 22nd March to 31st May 2020. Patient characteristics, management details, and outcomes were analysed. Results: A total of 102 hand injuries were encountered. Five patients were COVID-19 positive. The mean age was 28.9 ± 14.8 years and eighty-two (80.4%) were males. Thirty-one injuries involved fractures/dislocations, of which 23 (74.2%) were managed non-operatively. Seventy-five (73.5%) patients underwent wound wash or procedure under local anaesthetic and were discharged as soon as they were comfortable. Seventeen cases performed under brachial-plexus block, were discharged within 24 hours except four cases of finger replantation/ revascularisation and one flap cover which were discharged after monitoring for four days. At mean follow-up of 54.4 ± 21.8 days, the rates of early complication and loss to follow-up were 6.9% and 12.7% respectively. Conclusions: Essential trauma care needs to continue keeping in mind, rational use of resources while ensuring safety of the patients and health-care professionals. We need to be flexible and dynamic in our approach, by utilising teleconsultation, non-operative management, and regional anaesthesia wherever feasible.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleObservational Study
Indexed MeSH termsAdolescentAdultAnesthesia, GeneralAnesthetics, LocalBrachial Plexus BlockCOVID-19FemaleHand InjuriesHealth Services AccessibilityHumansIndiaLost to Follow-Up

Resumen

Retrospective observational study of 102 hand injuries during COVID-19 pandemic at a level-1 trauma center, including finger replantation/revascularization cases.

Por qué esto importa para la hirudoterapia

Este estudio observacional retrospectivo de un solo centro describe modificaciones del manejo para 102 pacientes con lesiones de mano durante la pandemia de COVID-19, centrándose en adaptaciones de la práctica como el mayor uso de anestesia local/regional, el manejo no quirúrgico y la teleconsulta. El estudio no menciona terapia con sanguijuelas, hirudoterapia ni manejo de la congestión venosa en ningún contexto. No existe relevancia defendible relacionada con sanguijuelas para el ámbito de la ASH en este artículo. El estudio aborda la logística de la prestación de atención médica durante una pandemia en lugar de cualquier modalidad terapéutica relacionada con el secretoma de la sanguijuela o la hirudoterapia.

Citación

Optimising hand surgery during COVID-19 pandemic.

Saha S et al. · The journal of hand surgery Asian-Pacific volume, 2021

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.